MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
1.160
+0.060
+5.45%
After Hours: 1.120 -0.04 -3.45% 17:40 09/26 EDT
OPEN
1.120
PREV CLOSE
1.100
HIGH
1.190
LOW
1.110
VOLUME
1.89M
TURNOVER
0
52 WEEK HIGH
3.810
52 WEEK LOW
0.6400
MARKET CAP
200.49M
P/E (TTM)
-2.3525
1D
5D
1M
3M
1Y
5Y
Calculating The Fair Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
Does the September share price for Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) reflect what it's really worth? Today...
Simply Wall St. · 5d ago
Cara Therapeutics Named Ryan Maynard as Chief Financial Officer
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately.
Benzinga · 09/12 10:05
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Gainers
Benzinga · 08/24 09:56
Aerie, Eargo lead healthcare gainers; Bright Minds, Assertio top losers
Gainers: Aerie Pharmaceuticals AERI +35%. Eargo (EAR) +25...
Seekingalpha · 08/23 14:01
Rigel Pharma adds ~7% to reach over two month high
The shares of clinical-stage biotech Rigel Pharmaceuticals, Inc. (NASDAQ:<a href="https://seekingalpha.com/symbol/RIGL?utm_medium=referral&utm_source=webull.com" title="Rigel Pharmaceuticals, Inc." target=...
Seekingalpha · 08/18 13:55
BLUE, VLDR and SPPI are among pre market gainers
Cedar Realty Trust (CDR) +204%. Codiak BioSciences (<a href="ht...
Seekingalpha · 08/18 12:26
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 08/18 12:11
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $15
HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $7 to $15.
Benzinga · 08/18 10:37
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.